Created at	Source	Raw Value	Validated value
May 19, 2021, 12:31 a.m.	usa	Occurrence of death within 60 days (primary end point, EU SolidAct part B);Occurrence of disease progression within 14 days (primary end point, EU SolidAct part A);SpO2/FiO2-ratio at day 5 (primary end point, phase 2 trials)	Occurrence of death within 60 days (primary end point, EU SolidAct part B);Occurrence of disease progression within 14 days (primary end point, EU SolidAct part A);SpO2/FiO2-ratio at day 5 (primary end point, phase 2 trials)